Targeting Osteosarcoma

Targeted drug delivery is very useful as it improves the therapeutic outcome in various disease treament, this system represent a promising strategy for improving therapeutic agents' efficacy, pharmacokinetic profiles, and selectivity to the target. As an acknowledged delivery system provider, Creative Biolabs offers a comprehensive list of targeted delivery services to help our clinets obtain ideal laboratory test results. Our professional technical scientists can not only save your valuable time but also provide highly sensitive and qualified products to help boost your projects.

Osteosarcoma

Osteosarcoma is the most common bone cancer and has a frequent incidence of both morbidity and mortality in pediatric oncology. Osteosarcoma is most common between the ages of 15 to 25 in adolescents, with a predilection for larger, more athletic or active young people. The tumor arises most often at the ends of long bones, with the distal femur, proximal tibia and proximal humerus being the most common sites identified. Patients can be treated with pain killers or physical therapy for weeks or even months before an x-ray is obtained that shows the abnormality. Radiographs results show either a lytic lesion of bone or a bone mass with an adjacent soft tissue mass containing calcification. Currently, the diagnosis of osteosarcoma only relies on a clinical pathology diagnosis, since there is no characteristic mutation or immunohistochemical marker that defines the disease. Besides, conventional therapy for osteosarcoma has reached a plateau of 60-70%, a five-year survival rate that has changed little in two decades, implying now need some new approaches.

Fig.1 Osteogenesis and Osteosarcoma genesis.¹

Delivery System Targeting Osteosarcoma

Osteosarcoma therapy based on nanotechnology-based drug delivery systems to reduce the cytotoxicity of antineoplastic drugs and improve their pharmacokinetics is under assessed actively. Recently, a keratin nanoparticle serves as a novel drug delivery system to treat osteosarcoma. This natural biopolymer is a cysteine-rich structural protein, highly biocompatible and with exclusive tri-peptidic sequences present on its backbone, that can specifically combine vitronectin integrin receptors which are over-expressed by osteosarcoma cells. Moreover, keratin displays higher drug-loading ability, yields, reproducibility, and easier scalability, because of its unique structural and chemical features. The efficacy of PTX-Ce6@Ker was tested on osteosarcoma tumor cell lines, and results showed that PTX retains its activity while being vehiculated through keratin. Moreover, PTX and Ce6 act in an additive manner, suggested that the combination of the cytostatic blockage of PTX and the oxidative damage of ROS when light irradiation has a more potent effect compared to singularly administered PTX or Ce6. This is a novel nanotechnology-based drug delivery system for the treatment of osteosarcoma.

Fig.2 A schematic illustration of osteosarcoma cell internalization nanocarriers by active targeting.²

What Can We Do for You?

With well-developed module delivery systems, our experienced scientists are committed to providing high-quality targeted delivery services to contribute to the success of your project. Except for targeting osteosarcoma, Creative Biolabs also provides delivery systems for various other diseases. If you are interested in the service we provide, please feel free to contact us for more detail and information.

References

1. Xie, Duoli, et al. "Targeted delivery of chemotherapeutic agents for osteosarcoma treatment." Frontiers in Oncology 12 (2022): 843345.
2. Shi, Pengzhi, et al. "Active targeting schemes for nano-drug delivery systems in osteosarcoma therapeutics." Journal of Nanobiotechnology 21.1 (2023): 1-27.

Our services are For Research Use Only. We do not provide services to individuals.